Drugs in the Pipeline
Imbruvica is a first-in-class, oral Bruton's tyrosine kinase (BTK) inhibitor.
Drugs in the Pipeline
AstraZeneca announced that two pivotal Phase 3 registrational trials for benralizumab achieved their primary endpoint, demonstrating significant reductions in the annual asthma exacerbation rate compared to placebo.